In the phase III DETERMINATION trial, the addition of autologous stem cell transplantation (ASCT) to lenalidomide, bortezomib, and dexamethasone followed by lenalidomide maintenance to progression improved median progression-free survival by how many months (vs lenalidomide, bortezomib, and dexamethasone plus lenalidomide maintenance alone)?
